<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101035</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-67_301</org_study_id>
    <secondary_id>U1111-1114-4194</secondary_id>
    <nct_id>NCT01101035</nct_id>
  </id_info>
  <brief_title>Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)</brief_title>
  <acronym>CARES</acronym>
  <official_title>A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether subjects with gout who receive febuxostat or
      allopurinol for up to 9 years have a higher rate of serious heart and blood vessel
      complications (major cardiovascular events).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug tested in this study was called Febuxostat (TMX-67). Febuxostat compared with
      allopurinol was evaluated for the cardiovascular (CV) safety in people with gout and
      significant CV comorbidities.

      The study enrolled 6198 patients. Participants with a diagnosis of gout were enrolled in a
      1:1 ratio to receive either:

        -  Febuxostat

        -  Allopurinol

      Participants received febuxostat 40 mg or 80 mg for the study depending on their serum uric
      acid levels were either &lt;6.0 mg/dL or ≥6.0 mg/dL during specified visits. Allopurinol 200 mg
      to 400 mg (for moderate renal impairment),or 300 mg to 600 mg (for normal and mild renal
      impairment), increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL
      was received.

      This multi-center trial was conducted in Canada, Mexico and United States. The overall time
      to participate in this study was approximately 7 years (84 months). Participants made
      multiple visits to the clinic and were also contacted through the telephone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2010</start_date>
  <completion_date type="Actual">July 18, 2017</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Primary MACE Composite (Final Analysis)</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cardiovascular (CV) Death</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>Events were adjudicated by an independent cardiovascular endpoints committee as CV death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Non-fatal Myocardial Infarction (MI)</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Non-fatal Stroke</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization</measure>
    <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
    <description>Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6198</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat tablets</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <other_name>Uloric</other_name>
    <other_name>TMX-67</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol tablets</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <other_name>Zyloprim</other_name>
    <other_name>Allohexal</other_name>
    <other_name>Allosig</other_name>
    <other_name>Milurit</other_name>
    <other_name>Alloril</other_name>
    <other_name>Progout</other_name>
    <other_name>Zyloric</other_name>
    <other_name>Puricos</other_name>
    <other_name>Zyrik 300</other_name>
    <other_name>Aluron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant or the participant's legally acceptable representative signs and dates
             a written, informed consent form/Health Insurance Portability and Accountability Act
             (HIPAA) Authorization prior to the initiation of any study procedures.

          2. The participant is male ≥50 years of age or female ≥55 years of age and at least
             2-years post-menopausal.

          3. The participant has a history of major CV or cerebrovascular disease including at
             least one of the following:

               -  Myocardial infarction (MI).

               -  Hospitalized unstable angina.

               -  Cardiac or cerebrovascular revascularization procedure.

               -  Stroke.

               -  Hospitalized transient ischemic attack (TIA).

               -  Peripheral vascular disease (ankle brachial index ≤0.6, revascularization and/or
                  well-documented history of claudication).

               -  History of diabetes mellitus with evidence of micro- or macrovascular disease
                  (retinopathy, neuropathy, nephropathy, small vessel vascular diseases).

          4. The participant has a history or presence of gout defined as having one or more of the
             American Rheumatism Association criteria for the diagnosis of gout:

               -  A tophus proven to contain urate crystals by chemical or polarized light
                  microscopic means, and/or

               -  Characteristic urate crystals in the joint fluid, and/or

               -  History of at least 6 of the following clinical, laboratory, and X-ray phenomena:

                    -  More than 1 attack of acute arthritis.

                    -  Maximum inflammation developed within 1 day.

                    -  Monoarticular arthritis.

                    -  Redness observed over joints.

                    -  First metatarsophalangeal joint painful or swollen.

                    -  Unilateral first metatarsophalangeal joint attack.

                    -  Unilateral tarsal joint attack.

                    -  Tophus (proven or suspected).

                    -  Hyperuricemia.

                    -  Asymmetric swelling within a joint on x-ray.

                    -  Subcortical cysts without erosions on x-ray.

                    -  Joint fluid culture negative for organisms during attack.

          5. The participants must have either:

               -  a serum urate or serum uric acid (sUA) level ≥7.0 mg/dL (≥416 μmol/L) at the Day
                  -7 Visit OR

               -  a sUA level ≥6.0 mg/dL (≥354 μmol/L) at the Day -7 Visit AND inadequately
                  controlled gout (≥1 flare in the 12 months prior to screening and/or the presence
                  of tophi).

          6. The participant is capable of understanding and complying with protocol requirements

        Exclusion Criteria:

        Participants who meet any of the following criteria will not qualify for entry into this
        study:

          1. The participant has secondary hyperuricemia (eg, due to myeloproliferative disorder,
             or organ transplant).

          2. The participant has a history of xanthinuria.

          3. The participant has received urate-lowering therapy (i.e., febuxostat, allopurinol,
             probenecid, etc.) or excluded medication during the screening period (beginning with
             Day -7).

          4. The participant has a known hypersensitivity to febuxostat or allopurinol or any
             components of their formulation.

          5. The participant has active peptic ulcer disease.

          6. The participant has a history of cancer (other than basal cell carcinoma of the skin)
             within 5 years prior to the first dose of study medication.

          7. The participant had MI or stroke within 60 days prior to the Screening Visit.

          8. The participant has alanine aminotransferase (ALT) and/or aspartate aminotransferase
             (AST) values greater than 2 times the upper limit of normal (×ULN) during the
             Screening period.

          9. The participant has a significant medical condition and/or conditions that would
             interfere with the treatment, safety, or compliance with the protocol.

         10. The participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol abuse within 5 years prior to the Screening Visit or the
             participant consumes &gt;14 alcoholic beverages per week.

         11. The participant has received any investigational medicinal product within the 30 days
             prior to the Screening Visit and throughout the study.

         12. The participant's estimated creatinine clearance (CLcr) is &lt;30 mL/min, where CLcr is
             calculated using the Cockcroft and Gault formula based on ideal body weight (IBW),

         13. The participant is an immediate family member, study site employee, or is in a
             dependant relationship with a study site employee who is involved in conduct of this
             study (eg, spouse, parent, child, sibling) or may consent under duress.

         14. The participant is required to take excluded medications

         15. The participant has a known history of infection with hepatitis B, hepatitis C, or
             human immunodeficiency virus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waycross</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morton</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mer Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Gibson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarkson Valley</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradell</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freeport</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ephrata</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McMurray</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quakertown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orchard</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Berlin</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jalisco</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&amp;fileTypeCode=ULORICPI</url>
    <description>Uloric Package Insert</description>
  </link>
  <link>
    <url>http://www.goutstudynow.com/</url>
    <description>Additional Study Information</description>
  </link>
  <results_reference>
    <citation>White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012 Jul;164(1):14-20. doi: 10.1016/j.ahj.2012.04.011. Epub 2012 Jun 13.</citation>
    <PMID>22795277</PMID>
  </results_reference>
  <results_reference>
    <citation>White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.</citation>
    <PMID>29527974</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <results_first_submitted>May 11, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2018</results_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Outcomes</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>Stroke</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Physiology</keyword>
  <keyword>Hyperuricemia</keyword>
  <keyword>Uric Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01101035/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01101035/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 320 investigative sites in Canada, Mexico and United States from 23 April 2010 to 18 July 2017.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of gout and significant cardiovascular comorbidities were enrolled in a 1:1 ratio to receive either febuxostat or allopurinol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat</title>
          <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
        </group>
        <group group_id="P2">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3101"/>
                <participants group_id="P2" count="3097"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1704"/>
                <participants group_id="P2" count="1706"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1397"/>
                <participants group_id="P2" count="1391"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="595"/>
                <participants group_id="P2" count="587"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="363"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat</title>
          <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
        </group>
        <group group_id="B2">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3098"/>
            <count group_id="B2" value="3092"/>
            <count group_id="B3" value="6190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="8.58"/>
                    <measurement group_id="B2" value="65.0" spread="8.49"/>
                    <measurement group_id="B3" value="64.8" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1584"/>
                    <measurement group_id="B2" value="1506"/>
                    <measurement group_id="B3" value="3090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt;75 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1094"/>
                    <measurement group_id="B2" value="1135"/>
                    <measurement group_id="B3" value="2229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="420"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="500"/>
                    <measurement group_id="B3" value="994"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2604"/>
                    <measurement group_id="B2" value="2592"/>
                    <measurement group_id="B3" value="5196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="593"/>
                    <measurement group_id="B3" value="1145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2160"/>
                    <measurement group_id="B2" value="2140"/>
                    <measurement group_id="B3" value="4300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="539"/>
                    <measurement group_id="B2" value="521"/>
                    <measurement group_id="B3" value="1060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2559"/>
                    <measurement group_id="B2" value="2571"/>
                    <measurement group_id="B3" value="5130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2651"/>
                    <measurement group_id="B2" value="2665"/>
                    <measurement group_id="B3" value="5316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.9" spread="9.54"/>
                    <measurement group_id="B2" value="173.0" spread="9.77"/>
                    <measurement group_id="B3" value="173.0" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Here, number analyzed indicates participants who were evaluated for this baseline characteristic.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3087"/>
                    <count group_id="B3" value="6185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.5" spread="22.47"/>
                    <measurement group_id="B2" value="100.3" spread="22.89"/>
                    <measurement group_id="B3" value="100.4" spread="22.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <population>Here, number analyzed indicates participants who were evaluated for this baseline characteristic.</population>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3087"/>
                    <count group_id="B3" value="6185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" lower_limit="18" upper_limit="73"/>
                    <measurement group_id="B2" value="32.1" lower_limit="17" upper_limit="75"/>
                    <measurement group_id="B3" value="32.3" lower_limit="17" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI Categorical</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="844"/>
                    <measurement group_id="B2" value="862"/>
                    <measurement group_id="B3" value="1706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2053"/>
                    <measurement group_id="B2" value="2024"/>
                    <measurement group_id="B3" value="4077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1175"/>
                    <measurement group_id="B2" value="1124"/>
                    <measurement group_id="B3" value="2299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1533"/>
                    <measurement group_id="B2" value="1553"/>
                    <measurement group_id="B3" value="3086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="415"/>
                    <measurement group_id="B3" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never drank</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="792"/>
                    <measurement group_id="B2" value="784"/>
                    <measurement group_id="B3" value="1576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-drinker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="805"/>
                    <measurement group_id="B2" value="812"/>
                    <measurement group_id="B3" value="1617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current drinker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1501"/>
                    <measurement group_id="B2" value="1496"/>
                    <measurement group_id="B3" value="2997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Function</title>
          <description>Moderate renal impairment: eCLcr=30 to 59 mL/min; mild renal impairment: eCLcr=60 to 89 mL/min; normal: eCLcr ≥90 mL/min. Seven subjects with Baseline eCLcr &lt;30 mL/min and 1 subject with missing Baseline eCLcr</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Moderately Impaired</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1636"/>
                    <measurement group_id="B2" value="1631"/>
                    <measurement group_id="B3" value="3267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mildly Impaired</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1217"/>
                    <measurement group_id="B2" value="1231"/>
                    <measurement group_id="B3" value="2448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="228"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Kidney Stone</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="627"/>
                    <measurement group_id="B2" value="627"/>
                    <measurement group_id="B3" value="1254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2471"/>
                    <measurement group_id="B2" value="2465"/>
                    <measurement group_id="B3" value="4936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of Low Dose Aspirin</title>
          <description>Dosing &lt;325 mg aspirin per day is considered as low-dose aspirin</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1496"/>
                    <measurement group_id="B2" value="1481"/>
                    <measurement group_id="B3" value="2977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1602"/>
                    <measurement group_id="B2" value="1611"/>
                    <measurement group_id="B3" value="3213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of any Dose of Aspirin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1894"/>
                    <measurement group_id="B2" value="1933"/>
                    <measurement group_id="B3" value="3827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1204"/>
                    <measurement group_id="B2" value="1159"/>
                    <measurement group_id="B3" value="2363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of Nonsteroidal Anti-Inflammatory Drug (NSAIDs)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="856"/>
                    <measurement group_id="B2" value="908"/>
                    <measurement group_id="B3" value="1764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2242"/>
                    <measurement group_id="B2" value="2184"/>
                    <measurement group_id="B3" value="4426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of Clopidogrel and Other Antiplatelet Drugs</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="599"/>
                    <measurement group_id="B2" value="627"/>
                    <measurement group_id="B3" value="1226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3098"/>
                    <count group_id="B2" value="3092"/>
                    <count group_id="B3" value="6190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2499"/>
                    <measurement group_id="B2" value="2465"/>
                    <measurement group_id="B3" value="4964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)</title>
        <description>Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)</title>
          <description>Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
          <population>Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3039"/>
                <count group_id="O2" value="3034"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for the primary endpoint was based on 1-sided repeated confidence intervals (CIs), using critical values from a 1-sided stopping boundary for a group sequential design (GSD), to preserve an overall false-rejection rate of 2.5%, to assess non-inferiority at each interim analysis and the final analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was declared if the upper 1-sided CI for the hazard ratio was less than 1.3. Critical boundary of 2.359 (75% interim) based on the Lan-DeMets-O’Brien-Fleming alpha spending function was used for CI estimation.</non_inferiority_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.99</param_value>
            <ci_percent>97</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of any MACE was fitted using Cox Proportional Hazard model with treatment as a covariate and Baseline renal function as a stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event</title>
        <description>APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event</title>
          <description>APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
          <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3098"/>
                <count group_id="O2" value="3092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of any APTC event was fitted using Cox Proportional Hazard model with treatment as a covariate and Baseline renal function status as a stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cardiovascular (CV) Death</title>
        <description>Events were adjudicated by an independent cardiovascular endpoints committee as CV death.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiovascular (CV) Death</title>
          <description>Events were adjudicated by an independent cardiovascular endpoints committee as CV death.</description>
          <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3098"/>
                <count group_id="O2" value="3092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of cardiovascular death was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Non-fatal Myocardial Infarction (MI)</title>
        <description>Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Non-fatal Myocardial Infarction (MI)</title>
          <description>Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.</description>
          <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3098"/>
                <count group_id="O2" value="3092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of non-fatal MI was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Non-fatal Stroke</title>
        <description>Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Non-fatal Stroke</title>
          <description>Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.</description>
          <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3098"/>
                <count group_id="O2" value="3092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of non-fatal stroke was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization</title>
        <description>Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization</title>
          <description>Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.</description>
          <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3098"/>
                <count group_id="O2" value="3092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of unstable angina with urgent coronary revascularization was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Primary MACE Composite (Final Analysis)</title>
        <description>Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
        <time_frame>Up to last dose of study drug (approximately 83 months)</time_frame>
        <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary MACE Composite (Final Analysis)</title>
          <description>Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.</description>
          <population>FAS included all participants who were randomized and received at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3098"/>
                <count group_id="O2" value="3092"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for the primary endpoint was based on 1-sided repeated confidence intervals (CIs), using critical values from a 1-sided stopping boundary for a group sequential design (GSD), to preserve an overall false-rejection rate of 2.5%, to assess non-inferiority at each interim analysis and the final analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was declared if the upper 1-sided CI for the hazard ratio was less than 1.3. Critical boundary of 2.014 (final analysis) based on the Lan-DeMets-O’Brien-Fleming alpha spending function was used for CI estimation.</non_inferiority_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.03</param_value>
            <ci_percent>97</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Time from randomization to the first occurrence of any MACE was fitted using Cox Proportional Hazard model with treatment as a covariate and Baseline renal function as a stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug to 30 days after last dose of study drug (Approximately 84 months)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat</title>
          <description>Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.</description>
        </group>
        <group group_id="E2">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was &lt;6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but &lt;60 mL/min).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version: 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1046" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="995" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Defect conduction intraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <description>Three treatment-emergent deaths occurred during treatment with febuxostat and are not related.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with febuxostat and are not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with febuxostat and are not related.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>Ten treatment-emergent deaths occurred during treatment with febuxostat and are not related; Eight treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with febuxostat and are not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>Five treatment-emergent deaths occurred during treatment with febuxostat and are not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Eleven treatment-emergent deaths occurred during treatment with febuxostat and are not related; Seven treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Subendocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with febuxostat and are not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chronotropic incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Eleven treatment-emergent deaths occurred during treatment with febuxostat and are not related; Eight treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <description>Four treatment-emergent deaths occurred during treatment with febuxostat and are not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sudden visual loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Poor dental condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Volvulus of small bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Colonic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Mesenteric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vomiting projectile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Five treatment-emergent deaths occurred during treatment with febuxostat and are not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Implant site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Necrobiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Surgical failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Granulomatous liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Incisional hernia gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oral bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>CNS ventriculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Herpes simplex meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Herpes zoster meningomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Abscess rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Six treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with febuxostat and are not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Staphylococcal parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vascular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Epidural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Open globe injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Psychosis postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>Three treatment-emergent deaths occurred during treatment with febuxostat and are not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Failure to anastomose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tracheostomy malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prothrombin time ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cardioactive drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Influenza B virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vertebral osteophyte</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pleomorphic malignant fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Benign anorectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tumour ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ductal adenocarcinoma of pancreas</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <description>Three treatment-emergent deaths occurred during treatment with febuxostat and are not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Kidney angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with febuxostat and are not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Three treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Poorly differentiated thyroid carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Slow speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spinal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cerebral ventricle dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device lead issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Shared psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Substance use disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <description>Two treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>Three treatment-emergent deaths occurred during treatment with allopurinol and are not related.</description>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant renal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Laryngeal dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <description>One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <description>Seven treatment-emergent deaths occurred during treatment with febuxostat and are not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related. One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Five treatment-emergent deaths occurred during treatment with febuxostat and are not related; Seven treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <description>One treatment-emergent death occurred during treatment with febuxostat and is not related; One treatment-emergent death occurred during treatment with allopurinol and is not related.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Aortic calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version: 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1450" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="1467" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="284" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="267" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="311" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="3092"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="3098"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="3092"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

